Your browser does not support JavaScript!

FranceBiotechnologies

FranceBiotechnologies est une plateforme pour découvrir les actualités, entreprises, produits et savoir-faire techniques de la biotechnologies. Partagez et échangez entre spécialistes.

Rejoignez la communauté
Une actualité de FierceBiotech a été ajouté(e)
Il y a 2 jours

Bischofberger-helmed Kronos bags $105M to tackle tough targets

Il y a 3 jours
Kronos Bio has raised $105 million. The series A sets the Norbert Bischofberger-helmed biotech up to advance efforts to hit historically undruggable targets. ...
www.fiercebiotech.com
Bandeau FranceBiotechnologies
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 2 jours

Dutch Biotech Prepares for Acute Kidney Injury Clinical Trial with €116M Fundraise

Il y a 5 jours
The Dutch company AM-Pharma has raised €116M ($133M) to fund a phase III trial of its recombinant protein drug for treating acute kidney injury, a disease with no approved treatments. “This is...
labiotech.eu
Une actualité de L'Usine Nouvelle a été ajouté(e)
Il y a 2 jours

Abaissement à 90% du seuil de retrait obligatoire : quel impact pour les biotechs/medtechs

Il y a 3 jours
De nombreuses biotechs/medtechs françaises ont eu recours ces dernières années aux marchés boursiers pour financer leur croissance et dans leur... - Cabinet Dechert
www.usinenouvelle.com
Une actualité de FierceBiotech a été ajouté(e)
Il y a 2 jours

Eisai’s prototype blood test for Alzheimer’s shows links to CSF amyloid in early disease

Il y a 3 jours
New research from Eisai showed measurable correlations between amyloid biomarkers in the bloodstream and changes in the cerebrospinal fluid, bringing the company a step closer to developing a quick...
www.fiercebiotech.com
Une actualité de FierceBiotech a été ajouté(e)
Il y a 2 jours

EuroBiotech: More Articles of Note

Il y a 3 jours
In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug....
www.fiercebiotech.com
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 2 jours

Swiss Pneumonia Antibiotic Abandoned in Phase III

Il y a 3 jours
The Swiss biotech Polyphor has discontinued two phase III trials of its antibiotic for treating pneumonia after halting both trials due to safety concerns in May. The two phase III trials were testing...
labiotech.eu
Une actualité de FierceBiotech a été ajouté(e)
Il y a 2 jours

EuroBiotech Report—Gilead-Galapagos, Alzheimer's fail, AM-Pharma and Abivax

Il y a 3 jours
In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million....
www.fiercebiotech.com
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 2 jours

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

Il y a 3 jours
The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more. This IPO is one of the biggest...
labiotech.eu
Une actualité de FierceBiotech a été ajouté(e)
Il y a 2 jours

Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M

Il y a 3 jours
Nearly five years after lung-scarring med Ofev got the FDA nod, its maker wants to get cracking on a successor. Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics...
www.fiercebiotech.com
Une actualité de FierceBiotech a été ajouté(e)
Il y a 3 jours

Immusoft names former Amgen biologics chief as chief scientific officer

Il y a 4 jours
Immusoft has named Robert Hayes as chief scientific officer. Hayes, the former head of biologics at Amgen, joins the cell therapy startup as it works to move a treatment for mucopolysaccharidosis type...
www.fiercebiotech.com
Charger plus d'actualités